Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jonsson Comprehensive Cancer Center
With
Prostate Cancer Foundation
PRIMARY OBJECTIVE:
I. To define the biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues of patients with prostate cancer.
SECONDARY OBJECTIVES:
I. To evaluate whether 68Ga-FAPi-46 and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) accumulation observed by positron emission tomography (PET) correlates with the amount of fibroblast activation protein (FAP) and prostate specific membrane antigen (PSMA) in excised cancer tissue, respectively.
II. To assess the 68Ga-FAPI-46 biodistribution correlation with 68Ga-PSMA-11.
OUTLINE:
Patients receive 68Ga-FAPi-46 intravenously (IV) and undergo PET/computed tomography (CT) imaging over 20-50 minutes.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients who underwent a 68Ga-PSMA-11 PET/CT scan within 3 months of enrollment
Patients who are scheduled to undergo surgical excision or biopsy of a prostate cancer primary, recurrent or metastatic lesion
Patients can provide written informed consent
Patients are able to remain still for duration of imaging procedure (up to one hour)
You may not be if
Patients with any new prostate therapy between the PSMA PET/CT and the FAP inhibitor (FAPI) PET/CT
